Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
[Dilip Davda] The company is in the business of medical equipment/disposable manufacturing and marketing. It has reported steady growth in its top and bottom lines in recent years. Based on FY23 earnings, the issue appears reasonably priced. Investors may consider investment for the medium to long-term rewards. Read detail review...
Hemant Surgical Industries Limited peer comparison with similar listed entities. () (As on March 31, 2022)
| Company Name | EPS (Rs) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | |
|---|---|---|---|---|---|
| EPS Basic | EPS Diluted | ||||
| Hemant Surgical Industries Limited | 10.26 | 10.26 | 31.70 | 32.42 | |
| Poly Medicure Ltd. | 15.28 | 15.28 | 113.40 | 64.34 | 13.47 |
Hemant Surgical Industries IPO Reviews, analysis and views by popular members. Read Hemant Surgical Industries Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
Useful Articles
RHP